Home
#Global Trends
#Vietnam
#M&A
#Regulations
#Knowledge

Category: Uncategorized

Eli Lilly allocates additional $4.5B to expand Indiana manufacturing footprint

12/05/2026 Published by vivi

Eli Lilly and Company has announced a further $4.5 billion investment across two of its sites in Lebanon, Indiana. This... Read more

Tags: #Global Trends

GSK and SBP Group partner to accelerate the launch of Hepatitis B therapy in China

12/05/2026 Published by vivi

Pharmaceutical giant GSK has entered into an exclusive collaboration with Sino Biopharmaceutical (SBP Group), specifically through its subsidiary Chia Tai... Read more

Category: Uncategorized

Tags: #Global Trends

Johnson & Johnson launches “Generation Fine” to reshape depression treatment goals

11/05/2026 Published by vivi

Johnson & Johnson has introduced a new advocacy project titled "Generation Fine," aimed at reshaping the conversation around clinical depression.... Read more

Category: Uncategorized

Tags: #Global Trends

Thế Giới Di Động’s pharmacy chain nears break-even point with 2026 profit goal

11/05/2026 Published by vivi

After nearly eight years in the pharmaceutical retail sector, the An Khang pharmacy chain is approaching financial stability following a... Read more

Category: Uncategorized

Tags: #Vietnam

Artificial intelligence emerges as a strategic economic driver for Vietnamese enterprises

11/05/2026 Published by vivi

The digital transformation landscape in Vietnam is witnessing a significant shift as Artificial Intelligence (AI) permeates the supply chains of... Read more

Category: Uncategorized

Tags: #Vietnam

AstraZeneca scales up collaboration with Immunai for AI-driven immune profiling

10/05/2026 Published by vivi

AstraZeneca has confirmed an extension of its technical partnership with the biotech firm Immunai, committing up to $37.5 million in... Read more

Category: Uncategorized

Tags: #Global Trends

BMS gets EU approval for Sotyktu for treatment of active psoriatic arthritis

09/05/2026 Published by vivi

Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Sotyktu (deucravacitinib) for the treatment of active... Read more

Category: Uncategorized

Tags: #Global Trends

Gilead cranks up Yeztugo first-year sales forecast to $1B on “unprecedented launch trajectory”

09/05/2026 Published by ViNe

Gilead Sciences has revised its 2026 sales forecast for Yeztugo (lenacapivir), its twice-yearly HIV pre-exposure prophylaxis (PrEP) medication. Following a... Read more

Category: Uncategorized

Tags: #Global Trends